Depomed Licenses Acuform® Patents to Janssen Pharmaceuticals, Inc. MENLO PARK, Calif., Aug. 27, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that Janssen Pharmaceuticals, Inc., ...
BURLINGTON, Mass. and MENLO PARK, Calif., June 20, 2011 (GLOBE NEWSWIRE) -- inVentiv Health, offering best-in-class clinical, consulting and commercial services to the healthcare industry, and Depomed ...
Up to $64M in milestone payments could be realized. Covidien has licensed worldwide rights to utilize Depomed’s AcuForm™ gastric retentive drug delivery technology for the exclusive development of ...
MENLO PARK, Calif., Oct 12, 2009 -- Depomed, Inc. (NASDAQ:DEPO) announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an ...
Biovail shells out upfront fee of $500,000. Biovail gained access to Depomed’s AcuForm™ drug delivery technology for the development of up to two products. Biovail may select these products from an ...
Depomed Comments on FDA Guidance and Plans for One Additional Phase 3 Clinical Trial Evaluating Non-Hormonal Therapy for Menopausal Hot Flashes MENLO PARK, Calif., Jan 19, 2010 (BUSINESS WIRE) -- ...
MENLO PARK, Calif., Sept. 17, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the UBS Global ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson’s patients, DM-1992, Depomed’s investigative novel gastric ...
MENLO PARK, Calif., Aug. 27, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results